null

null

null

null

null

null

null

null

null

0.06x Total Debt / Equity (Conservative)

Low direct sensitivity; no significant debt load, but rising rates increase burn rate pressure on cash reserves funding R&D operations

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Single-source API manufacturers in China for menin inhibitor synthesis; U.S.-China trade tensions and FDA import controls are top chokepoints

Minimal international revenue currently; clinical trials primarily U.S.-based, so sovereign currency devaluation exposure is negligible

Predominantly U.S.-based operations; no material international revenue markets, making currency devaluation exposure effectively zero

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

CROs like Covance/Labcorp represent non-substitutable clinical trial execution partners; switching mid-trial would cause 12-18 month delays and regulatory risk

Cloud disruption risk is low; core IP resides in molecular compounds and clinical data, not software infrastructure dependent on single cloud provider

Pre-commercial biopharma; no secondary cloud-dependent business model exists; operations could migrate within 60-90 days with manageable disruption

API coupling risk is minimal; company uses standard clinical trial software (Medidata/Veeva); switching costs are moderate at ~$2-5M and 6-month delay

Low Howey Test risk; equity shares in a development-stage biopharma represent ownership in enterprise, not a passive profit-sharing investment contract

Very High

Moderate GDPR exposure from EU clinical trial patient data; CCPA exposure limited; compliance costs estimated $1-3M annually for trial data management

Low antitrust risk; single-asset oncology company with no market dominance; menin inhibitor space has multiple competitors including Syndax and Syndax

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Currently 0% recurring revenue; 100% transactional via potential milestone payments and future drug sales; pre-commercial stage with no product on market

Future monetization via drug sales (tipifarnib, ziftomenib) and potential licensing/partnership milestones; partnered with Jazz Pharmaceuticals for commercialization

Oncology drug pricing estimated $150,000-$300,000/year per patient based on comparable AML therapies; pricing power dependent on FDA approval and label breadth

Moderate-high pricing power if approved; rare hematologic oncology indication with limited competition supports premium pricing with payer negotiation risk

Expected 75-85% gross margin post-commercialization, consistent with specialty oncology drug peers; COGS dominated by manufacturing and royalties

No free-rider problem; prescription oncology drugs require physician authorization and payer approval, creating inherent access controls with no free-rider leakage

Revenue growth is sublinear to headcount; commercial launch requires sales force build (~150-200 reps) but manufacturing scales independently of headcount

Marginal cost of growth is primarily manufacturing scale-up and clinical expansion; incremental revenue from new indications has high operating leverage post-approval

Not applicable; Kura Oncology is not a franchise business model

At 10x scale, customer acquisition cost (oncologist outreach) decreases via brand recognition; estimated CAC per prescribing physician ~$15,000-$25,000

No traditional network effects; clinical data breadth creates modest knowledge moat but prescriber adoption is linear, not exponential network-driven

-37.7% Return on Assets (Negative equity)

High recession resistance; oncology treatment is non-discretionary; AML patients continue therapy regardless of economic cycle; payer mix risk is primary concern

Oncologists and hematologists treating AML/MDS patients; top 200 academic medical centers represent ~60-70% of addressable patient volume

Specialty pharmacy distributors and hospital formulary committees as secondary gatekeepers; GPO contracts and payer coverage decisions drive secondary segment risk

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

9.8% CapEx / Revenue (Moderate-CapEx)

0001422143

KURA